Premium
Letter: infliximab and adalimumab in the management of C rohn's disease – are they really comparable?
Author(s) -
LopezSanroman A.,
Gisbert J. P.
Publication year - 2012
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2012.05185.x
Subject(s) - infliximab , medicine , adalimumab , disease , adverse effect , crohn's disease , clinical trial , intensive care medicine